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It is estimated that 20 million people in
India fall below the poverty line each year
because of indebtedness due to healthcare
needs (PricewaterhouseCoopers, 2007).
This is indeed an alarming figure. Just to
put things into perspective, the popula-
tion of the financial capital of our country,
Mumbai, is around 12 million and that of
the national capital, Delhi, is 10 million.
Now, imagine a population, the size of an
entire city, going bankrupt. Only 11% of
the Indian population have health insur-
ance coverage (PricewaterhouseCoopers,
2007). Thus, everyone outside this 11%
and those who don’t fall in the upper mid-
dle and upper socio-economic classes, is
at a risk of going bankrupt, God forbid, if
they were to encounter a health crisis.
Total health care costs can be divided
into two major components: cost of
medicines and other costs. We would like
to highlight the cost of medicines as a sep-
arate chunk because, the average Indian
household may spend about 50% of their
total health expenditures on medicines
alone. According to the National Sample
Survey (NSS) for the year 1999–2000, in
rural India, the share of drugs in the
total Out of Pocket expenditure (OPP)
was estimated to be nearly 83%, while in
urban India, it was 77% (NPPP, 2011).
The other costs include doctor’s fees, med-
ical/surgical procedure costs, laboratory
test costs, in-hospital costs and so on. And
there are the intangible costs that are dif-
ficult to estimate but nevertheless assume
significant proportions. It is important to
note that most of the health insurance
schemes pay the in-hospital costs only.
Inflation is touching a new high and
the rupee is touching a new low. The
cost of living is steadily increasing whereas
the incomes of individuals are increas-
ing at much lower rates. In India, the
mighty “gold” and the acrid “onions”
have been in the news for being one
of the priciest commodities putting them
out of the common man’s reach. But
drug prices are outstripping all commodi-
ties (Selvaraj, 2007). An examination of
the price trends of 152 drugs in India,
reveals that antibiotics, anti-tuberculosis
and anti-malarial drugs, and drugs for
cardiac disorders, etc. registered price
increments from 1 to 15% per annum dur-
ing 1976–2000 (National Commission on
Macroeconomics and Health Ministry of
Health and Family Welfare Government
of India, 2005). The reason being that
only one-tenth of drug market is price
controlled as against nearly 90% dur-
ing the late 1970s (Government of India,
2005).
If this was not enough, both commu-
nicable and lifestyle diseases are increasing
at alarming proportions. It is estimated
that by 2015 the number HIV/AIDS cases
would be three times more than that in
2005, entailing possibly a corresponding
increase in the existing prevalence level
of tuberculosis of about 85,00,000 cases.
Cardiovascular diseases and diabetes will
more than double. Cancers will rise by
25%. In the coming 5 years there will be
an enormous increase in various health
disorders thereby increasing the healthcare
costs geometrically (National Commission
on Macroeconomics and Health Ministry
of Health and Family Welfare Government
of India, 2005).
At such times, the decision of
the National Pharmaceutical Pricing
Authority (NPPA), to regulate prices of
348-odd essential medicines by means
of the Drugs Prices Control Order 2013,
is a welcome respite (Department of
Pharmaceuticals, 2013). But how long
will this step go in mitigating the double
blow of increasing disease and skyrock-
eting prices, only time will tell. Many
loopholes have been cited in the DPCO
(First Post – India, 2013; Rajagopal, 2013;
Venkiteswaran, 2013). Some of them are
as follows:
1. Only drugs on the National List of
Essential Medicines (NLEM) will be
included. The NLEM has itself been
criticized for improper selection of
drugs (Manikandan and Gitanjali,
2013).
2. Manufacturers might change dosages
and formulations to avoid the DPCO.
3. “Market based pricing” has been used
to determine the ceiling price.
The past experiences have not been good,
because in 2008 the government had
initiated a similar program called as
the “Jan Aushadhi” program, that hit
many roadblocks and was not success-
ful at what it had purported (Jayaraman,
2010; Alexander, 2012). The private
sector accounts for more than 80%
of total health care spending in India
(PricewaterhouseCoopers, 2007). Unless
there is a decline in the combined cen-
tral and state government deficit, which
stands at roughly 8.5% as of 2012–13, the
opportunity for significantly higher pub-
lic health spending will also be limited
(Government of India, 2013).
The government of India has started the
Rashtriya Swasthya Bima Yojana (RSBY),
literally “National Health Insurance
Programme” for individuals below the
poverty line in 2008. It provides annual
hospitalization cover up to Rs. 30,000 or $
485 for a family of five members through
health insurance companies (Ministry
of Labour, and Employment, 2013). But
again it doesn’t cover the outpatient costs.
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Also, it has been said that the coverage
under the scheme is less than desirable
and as a result many poor still remain
uninsured (Dhoot, 2011, 2013). The exact
impact of the scheme still remains to be
evaluated (Dhoot, 2013). Another piece
of irony is that since many villages do not
even have hospitals, some of these hos-
pitalization schemes can’t be used at all
(Sinha, 2012).
Pharmacoeconomics research can take
us toward the final aim of making drugs
affordable to all. Though pharmacoeco-
nomics is in its infancy in India, it is
rapidly evolving and good quality studies
are being conducted across the nation. The
first proposed Pharmacoeconomics guide-
lines draft was recently prepared by experts
in the field (Gupta et al., 2013). This
notwithstanding, overall, for the com-
mon man, the situation doesn’t look very
promising and a lot needs to be done to
make medicines affordable to all.
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